BP wins arbitration case against Venture Global over LNG cargoes-March 2024-www.financetom.com

BP wins arbitration case against Venture Global over LNG cargoes

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

BP wins arbitration case against Venture Global over LNG cargoes

Oct 9, 2025 2:05 PM

HOUSTON, Oct 9 (Reuters) - BP has won its

arbitration case against Venture Global ( VG ) over the U.S.

supplier's failure to deliver liquefied natural gas under a

long-term contract that was due to start in late 2022, Venture

Global ( VG ) said on Thursday.

Previous page： --AbbVie Completes Acquisition of Cerevel Therapeutics Next page： Huntington Ingalls' Q2 Earnings, Revenue Increase

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

--AbbVie Completes Acquisition of Cerevel Therapeutics

Aug 1, 2024

08:37 AM EDT, 08/01/2024 (MT Newswires) -- Price: 185.30, Change: -0.02, Percent Change: -0.01 ...

Huntington Ingalls' Q2 Earnings, Revenue Increase

Aug 1, 2024

08:37 AM EDT, 08/01/2024 (MT Newswires) -- Huntington Ingalls Industries ( HII ) reported Q2 earnings Thursday of $4.38 per diluted share, up from $3.27 a year earlier. Analysts polled by Capital IQ expected $3.60. Sales and service revenue for the quarter ended June 30 was $2.98 billion, compared with $2.79 billion a year earlier. Analysts surveyed by Capital IQ...

Alnylam Pharmaceuticals Swings to Q2 Adjusted Earnings, Revenue Increases

Aug 1, 2024

08:42 AM EDT, 08/01/2024 (MT Newswires) -- Alnylam Pharmaceuticals ( ALNY ) reported Q2 adjusted earnings Thursday of $0.56 per diluted share, compared with an adjusted loss of $1.62 a year earlier. Analysts polled by Capital IQ expected an adjusted loss of $0.69. Revenue for the quarter ended June 30 was $659.8 million, compared with $318.8 million a year earlier....

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Aug 1, 2024

Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs. U.S. sales of...